Get the Stockscreener App
851.21
2.61%
-22.79
Pre-market:
853.58
2.37
+0.28%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $851.21, with a volume of 3.88M.
It is down -2.61% in the last 24 hours and down -3.08% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$874.00
Open:
$866.04
24h Volume:
3.88M
Relative Volume:
1.24
Market Cap:
$760.43B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
37.68
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-7.63%
1M Performance:
-3.08%
6M Performance:
+4.63%
1Y Performance:
-3.84%
1-Day Range:
$850.51
$869.02
1-Week Range:
$850.51
$930.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
851.21 | 780.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.35 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
203.89 | 349.67B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
185.20 | 289.51B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
110.95 | 271.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
The Stepwise Path Lilly Mapped From Paper To Digital Logbooks - Bioprocess Online
Eli Lilly’s $20.9 Billion M&A Spree Signals a Strategic Pivot Ahead of a Pivotal Earnings Report - AD HOC NEWS
Is Eli Lilly (LLY) Offering A Chance After Recent Share Price Pullback? - simplywall.st
Lilly signs $2.25B deal with California AI firm to develop genetic medicine - Inside INdiana Business
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Sun Pharma, Lilly Lead Latest Healthcare Deal Rush - marketscreener.com
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings - Investopedia
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact - Pharmaceutical Technology
Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine - dailyjournal.net
Novo Nordisk A/S Stock (NVO) Moved Down by 3.07% on Apr 29: Drivers Behind the Movement - TradingKey
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals - Insider Monkey
Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs - TipRanks
What triggered Eli Lilly shares' latest price pullback - Traders Union
Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - GlobeNewswire Inc.
Eli Lilly Stock (LLY) Opinions on Foundayo Pill Launch - Quiver Quantitative
AI Models Split on How Much Upside Is Left in Eli Lilly (LLY) - TipRanks
Eli Lilly investors are eager for Foundayo insight after early launch data - Reuters
Eli Lilly (LLY) Stock; Edges Higher as $2.25B AI Gene-Editing Deal Sparks Biotech Optimism - CoinCentral
Wegovy’s Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch - Seeking Alpha
Eli Lilly Expands Into AI DNA Editing With Profluent Enzyme Deal - simplywall.st
Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So - AOL.com
Boehringer’s obesity drug shows 16.6% weight loss; more data needed - statnews.com
FUTURHEALTH LEADS IN PROVIDING ELI LILLY'S ORAL GLP-1, ORFORGLIPRON, BROADENING ACCESS TO ADVANCED NON-INJECTABLE THERAPY - Intellectia AI
Eli Lilly, Profluent Target Complex Genetic Diseases With AI-Driven Custom DNA Tools - Benzinga
AI company Profluent strikes potential $2 billion deal with drugmaker Lilly - The Business Journals
FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment - PR Newswire
Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus - JD Supra
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion - Reuters
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
Profluent Partners with Eli Lilly (LLY) in $2.25B Drug Developme - GuruFocus
Lilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio - European Pharmaceutical Review
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing - Fierce Biotech
Analysts Are Bullish on Top Healthcare Stocks: UnitedHealth (UNH), Eli Lilly & Co (LLY) - The Globe and Mail
Lilly, Profluent ink deal on AI drugs worth up to $2.25 billion - MSN
Eli Lilly inks gene therapy deal worth up to $2.25B with Profluent - Seeking Alpha
Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion - Bloomberg.com
Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine - Business Wire
From weight loss to wakefulness: Has Eli Lilly found the next goldmine? - medwatch.com
Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion - qz.com
Pharmaceutical Stock Pulling Back Before Earnings - Schaeffer's Investment Research
Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition - Insider Monkey
Eli Lilly’s Oncology Push Sparks S&P 500 Futures Buzz - Kalkine Media
Eli Lilly (LLY) Anticipates Strong Q1 Earnings Growth Driven by Obesity Treatments - GuruFocus
Eli Lilly Expands Oncology With Ajax Deal As Valuation Gap Persists - Yahoo Finance
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly Expands Oncology Portfolio with $2.3B Acquisition - Powder & Bulk Solids
Bernard Fox: Eli Lilly’s $7B Acquisition of Kelonia is a Leap Toward Democratizing CAR-T - Oncodaily
Jim Cramer Says Eli Lilly “Will Tell a Good Story When It Reports” - Insider Monkey
Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy - Law360
Eli Lilly’s Been On An Acquisition Spree This Year – Here’s A Look At Its Major Deals - Stocktwits
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
3.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):